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Introduction
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D)
is an inheritable heart muscle disease that predominantly affects the
right ventricle (RV) and predisposes to ventricular arrhythmias and
sudden cardiac death (SCD).1 –17
In the last three decades, there have been a significant number of
studies defining the pathogenesis, genetic aspects, and clinical manifes-
tations of the disease (See ‘Etiology, pathogenesis, diagnosis and natural
history’ as Supplementary material online). In 1994 and 2010, an Inter-
national Task Force (ITF) document proposed guidelines for the stan-
dardized diagnosis of ARVC/D based on electrocardiographic (ECG),
arrhythmic, morphological, histopathological, and clinico-genetic
factors.18,19
The growing knowledge regarding arrhythmic outcome, risk
factors, and life-saving therapeutic interventions, make it particularly
timely to critically address and place into perspective the issues rele-
vant to the clinical management of ARVC/D patients. The present ITF
consensus statement is a comprehensive overview of currently used
risk stratification algorithms and approaches to therapy, either
pharmacological or non-pharmacological, which often poses a clinic-
al challenge to cardiovascular specialists and other practitioners, par-
ticularly those infrequently engaged in the management of ARVC/D.
This document should be regarded as a guide to clinical practice
where rigorous evidence is still lacking, because of the relatively
low disease prevalence and the absence of controlled studies.
Recommendations are based on available data derived from non-
randomized and observational studies and consensus within the con-
ference panellists. When development of prognostic-therapeutic
algorithms was controversial, management decisions were recom-
mended to be individualized.
Recommendation and level of evidence of specific management
options were classified according to predefined scales, as outlined
in Tables 1 and 2 (http://www.escardio.org/guidelines-surveys/esc-
guidelines/about/Pages/rules-writing.aspx). Because randomized
studies arenot available, most consensus recommendations on treat-
ment of ARVC/D are based on data derived from follow-up registries
and/or experts opinions (i.e. level of evidence B or C).
All members of the writing group of this consensus document
provided disclosure statements of all relationships that might present
conflicts of interest.
Risk stratification
The natural history of ARVC/D is predominantly related to ventricu-
lar electrical instability which may lead to arrhythmic SCD, mostly in
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young people and athletes.2,8,10 In advanced disease, progression of
RV muscle disease and left-ventricular involvement may result in
right or biventricular heart failure.3,4 The available outcome studies
are based on small patients cohorts followed for a relatively short
follow-up period (Table 3).22–36 The estimated overall mortality
rate varies among different studies, ranging from 0.08% per year
during a mean follow-up of 8.5 years in the series by Nava et al.20
to 3.6% per year during a mean follow-up of 4.6 years in the series
by Lemola et al.21
The adverse prognosis of ARVC/D patients has been initially over-
estimated by reports from tertiary referral centres largely composed
of patients referred because of their high-risk status or severe clinical
manifestations requiring specialized therapeutic interventions, such
as catheter ablation or implantable defibrillator (ICD).21,27,37,38
Studies from community-based patient cohorts and clinical screening
of familial ARVC/D reported a much lower overall annual mortality
rates (,1%).24,30– 32,36,39 These latter data provide a more balanced
view of the natural history of ARVC/D, in which the disease
may occur with no or relatively mild disability and without the neces-
sity for major therapeutic interventions.10,12 –17 The mechanism of
SCD in ARVC/D is cardiac arrest due to sustained ventricular tachy-
cardia (VT) or ventricular fibrillation (VF), which may occur as the
first manifestation of the disease in young people without previous
symptoms.2,7,40
Data from autopsy series and observational clinical studies on
ARVC/D have provided a number of clinical predictors of adverse
events and death. Table 3 reports the clinical variables identified as
independent predictors of poor outcome including malignant ar-
rhythmic events (i.e. SCD, cardiac arrest due to VF, appropriate
ICD interventions, or ICD therapy on fast VT/VF), non-SCD, or
heart transplantation, which were found in at least one published
multivariable analysis. Patients who have experienced sustained
VT or VF are at highest riskof experiencing life-threatening arrhythmic
events.22–24 Unexplained syncope has been associated with an
increased arrhythmic risk in some but not in all studies.22,25,26 Of
note, unexplained syncope is defined as a loss of consciousness that:
(i) occurs in the absence of documented ventricular arrhythmias
and/orcircumstancesclearly leading toreflex-mediatedchanges invas-
cular tone or heart rate such as a micturition, defaecation, cough, or
other similar conditions; and (ii) remains unexplained after a detailed
clinical evaluation aimed to exclude other cardiac or extracardiac
causes.25
Other independent risk factors for adverse events include
non-sustained VT on 24-h Holter monitoring’;25,26 dilation/
dysfunction of RV, left ventricle (LV), or both;21,22,27–30,39 male
gender;31,32 compound and digenic heterozygosity of desmosomal-
gene mutations;32 young age at the time of diagnosis;22,23 proband
status;31 inducibility at programmed ventricular stimulation;26,28,33
amount of electroanatomic scar34 and electroanatomic scar-related
fractionated electrograms;35 extent of T-wave inversion across
precordial and inferior leads;23,31,36 low QRS amplitude36 and QRS
fragmentation.36
Electrophysiological study
Electrophysiological study (EPS) is a valuable diagnostic test fordiffer-
ential diagnosis between ARVC/D and idiopathic right ventricular
outflow tract tachycardia and may provide useful information regard-
ing the VT inducibility for optimization of detection/discrimination
algorithms and effective antitachycardia pacing protocols
in patients undergoing ICD implantation.11,28 However, conflicting
data exist concerning the role of inducibility of sustained VT or VF
for prediction of long-term arrhythmic outcome in ARVC/D
patients.22,23,25,26,33 Discrepancies between the study results may
be explained by differences in arrhythmic endpoints (i.e. life-saving
vs. any appropriate ICD discharge).
The largest multicentre studies on ARVC/D patients who received
an ICD demonstrated that EPS is of limited value in identifying
patients at riskof arrhythmic cardiac arrest because of its low predict-
ive accuracy.22,25 In these studies, the reported incidence of ‘life-
saving’ ICD discharges for treatment of fast VT or VF did not differ
significantly in patients who were and were not inducible at EPS, re-
gardless of the specific indication for ICD implantation. The study by
Corrado et al.25 on the outcome of 106 ARVC/D patients receiving
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Table 1 Classes of recommendations
Classes of
recommendations
Definition Suggested
wording to use
Class I Evidence and/or general agreement that a given treatment or procedure is beneficial,
useful, effective.
Is recommended/is indicated
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the
given treatment of procedure.
Class IIa Weight of evidence/opinion is in favour of usefulness/efficacy. Should be considered
Class IIb Usefulness/efficacy is less well established by evidence/opinion May be considered
Class III Evidence or general agreement that the given treatment or procedure is not useful/
effective, and in some cases may be harmful
Is not recommended
Table 2 Levels of evidence
Level of evidence A Data derived from multiple randomized
clinical trials or meta-analysis
Level of evidence B Data derived from a single randomized
clinical trial or large non-randomized studies
Level of evidence C Consensus of opinion of the experts and/or
small studies, retrospective studies, registries.
D. Corrado et al.3228
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Table 3 Clinical variables associated with an increased risk of major arrhythmic events in arrhythmogenic right-ventricular cardiomyopathy/dysplasia*
Risk factor Definition Patients, n Study endpoint HR/OR 95% CI P-value References
Cardiac arrest Aborted SCD due to VF 132 ICD interventions on rapid VT/VF 79 6.8–90.6 ,0.001 Corrado et al. Circulation 200322
Unstable sustained VT Sustained (.30 s) VT causing syncope or
haemodynamic collapse
ICD interventions on rapid VT/VF 14 1.7–21.1 0.015
Sustained VT or VF VT lasting .30 s or VF 108 Any appropriate ICD intervention N/A N/A 0.003 Link et al. JACC 201423
VT lasting .30 s or VF 50 Cardiac death (SCD in 67% and heart
failure in 33%)
22.97 2.33–2.66 0.007 Watkins et al. Heart Rhythm 200924
Syncope Syncopal episodes unrelated to
extracardiac causes andoccurring in the
absence of documented ventricular
arrhythmias and/or circumstances
clearly leading to reflex-mediated
changes in vascular tone or heart rate
132 ICD interventions on rapid VT/VF 7.5 0.84–1.81 0.07a Corrado et al. Circulation 200322
Idem 106 Any appropriate ICD intervention 2.94 1.83–4.67 0.013 Corrado et al. Circulation 201025
ICD interventions on rapid VT/VF 3.16 1.39–5.63 0.005
N/A 50 Cardiac death (SCD in 67% and heart
failure in 33%)
10.73 1.88–61.8 0.008 Watkins et al. Heart Rhythm 200924
Non-sustained VT ≥3 consecutive ventricular beats with a
rate .100 beats/min, lasting ,30 s,
documented during exercise testing or
24-h Holter
84 Any appropriate ICD intervention 10.5 2.4–46.2 0.003 Bhonsale et al. JACC 201126
Idem 106 Any appropriate ICD intervention 1.62 0.96–4.62 0.068a Corrado et al. Circulation 201025
LV dysfunction Angiographic LV EF,55% 132 ICD interventions on rapid VT/VF 0.94 0.89–0.95 0.037 Corrado et al. Circulation 200322
Angiographic LV EF,40% 130 Cardiac death (SCD in 33% and heart
failure in 67%)
10.9 2.8–41.7 ,0.001 Hulot et al. Circulation 200427
Angiographic LV EF,55% 60 Any appropriate ICD intervention 1.94 0.93–4.05 0.078a Wichter et al. Circulation 200428
Echocardiographic LV EF,50% 61 Cardiac death and heart
transplantation (SCD in 53%, heart
failure death in 13%, heart
transplantation in 34%)
N/A N/A ,0.05 Lemola et al. Heart 200521
Angiographic LV EF,55% 313 Sudden cardiac death 14.8 2.37–53.5 ,0.001 Peters, J Cardiovasc Med 200739
RV dysfunction Angiographic RV EF,45% 60 Any appropriate ICD intervention 2.09 1.03–4.23 0.041 Wichter et al. Circulation 200428
FAC % per unit decrease 70 Composite (death in 0%, heart
transplantation in 7%, ventricular
fibrillation in 10%, sustained
ventricular tachycardia in 36%,
arrhythmic syncope in 4%).
1.08 1.04–1.12 ,0.001 Saguner, Circ Cardiovasc Imaging 201429
RV dilation RV end-diastolic area, cm2, per unit
increase
70 As above 1.05 1.01–1.08 0.004 Saguner, Circ Cardiovasc Imaging 201429
Right-atrial dilation Right atrium, short axis, mm, per unit
increase
70 As above 1.03 1.00–1.06 0.037 Saguner, Circ Cardiovasc Imaging 201429
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Table 3 Continued
Risk factor Definition Patients, n Study endpoint HR/OR 95% CI P-value References
Biventricular dysfunction Echocardiographic RV and LV dysfunction
(EF,50%)
96 Cardiac death and heart
transplantation (SCD in 30%, heart
failure death in 30%, death of
unknown cause in 5%, heart
transplantation in 35%)
6.3 2.17–17.5 ,0.001 Pinamonti, Eur Heart J 201130
Heart failure Clinical signs of RV heart failure 130 Cardiac death (SCD in 33% and heart
failure in 67%)
13.7 2.58–71.4 0.002 Hulot et al. Circulation 200427
Clinical signs or symptoms of congestive
heart failure
61 Cardiac death and heart
transplantation (SCD in 53%, heart
failure death in 13%, heart
transplantation in 34%)
N/A N/A ,0.05 Lemola et al. Heart 200521
Young age Per 5 years increment 132 ICD interventions on rapid VT/VF 0.77 0.57–0.96 0.007 Corrado et al. Circulation 200322
Per 1 year increment 108 ICD interventions on rapid VT/VF N/A N/A 0.03 Link et al. JACC 201423
Male gender 215 Composite (cardiac arrest in 9%, ICD
intervention in 22%, sustained VT in
69%)
1.8 1.2–2.8 0.004 Bhonsale et al. Circ AE 201331
134 Composite (SCD in 5%, cardiac arrest
27%, sustained VT 64%, ICD shock
5%)
2.76 1.19–6.41 0.02 Rigato et al. Circ Gen 201332
Complex genotype Compound or digenic heterozygosisity 134 Composite (SCD in 5%, cardiac arrest
27%, sustained VT 64%, ICD shock
5%)
3.71 1.54–8.92 0.003 Rigato et al. Circ Gen 201332
Proband status First family memberaffected by the genetic
defect who seeks medical attention
because of the occurrence of clinical
manifestations
215 Composite (cardiac arrest in 9%, ICD
intervention in 22%, sustained VT in
69%)
7.7 2.8–22.5 ,0.001 Bhonsale et al. Circ AE 201331
Inducible VT/VF VT or VF that lasted .30 s or required
termination because of haemodynamic
compromise
84 Any appropriate ICD intervention 4.5 1.4–15.0 0.013 Bhonsale et al. JACC 201126
N/A 60 Any appropriate ICD intervention 2.16 0.94–5.0 0.069a Wichter et al. Circulation 200428
N/A ICD intervention on fast VT/VF N/A N/A N/A
VT that lasted .30 s or required
termination because of haemodynamic
compromise. Induction of VF not
considered
62 Composite (cardiac death in 13%,
heart transplantation in 10%,
unstable VT/VF in 70%, syncope in
7%).
2.5 1.0–6.2 0.04 Saguner, Am J Cardiol 201333
Extent of electroanatomic
scar on RV endocardial
voltage mapping
low-voltage (,0.5 mV) areas on bipolar
electroanatomic voltage mapping. Per
5% increment.
69 Composite arrhythmic (SCD in 5%,
ICD intervention in 37%, sustained
VT in 58%)
1.6 1.2–1.9 ,0.001 Migliore et al. Circ AE 201334
Fragmented electrograms
on RV endocardial
voltage mapping
Multiple (.3) discrete deflections,
amplitude ,1.5 mV, and duration
.100 ms
95 Any appropriate ICD intervention 21.2 1.8–251.8 0.015 Santangeli et al. Heart Rhythm 201235
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an ICD for primary prevention reported that the positive and nega-
tive predictive value of inducibility for VT or VF was 35 and 70%, re-
spectively. In this study, the type of ventricular tachyarrhythmia
inducible at the time of EPS (i.e. VTor VF) did not predict a statistically
different arrhythmic outcome over the follow-up. The North Ameri-
can Multidisciplinary study on 98 ARVC patients receiving an ICD
confirmed that inducible VT or VF at pre-implant EPS did not
predict appropriate interventions on fast VT or VF during a mean
follow-up of 3.3 years.23 On the contrary, in the cohort of ARVC/
D patients reported in the Johns Hopkins studies, inducibility was
the most significant independent predictor of appropriate ICD
firing. However, in the study by Bhonsale et al.,26 the positive and
negativepredictivevaluesof inducibility were65and75%, respective-
ly, and a sizeable proportion of patients experienced ICD interven-
tions during follow-up despite a lack of inducibility of VT/VF.
Moreover, the predictive value of inducibility for ‘life-saving’ ICD dis-
charges was not demonstrated by either univariate or multivariate
analysis. In asymptomatic patients, Bhonsale et al.26 reported that
the combination of ≥2 factors such as inducibility at EPS, proband
status, non-sustained VT, and PVCs ≥1000/24 h, predicts an incre-
mental risk of appropriate ICD interventions; however, a statistically
significant association with life-saving shocks for treatment of rapid
VT or VF has not been demonstrated. In the study by Saguner
et al.33 inducible VT was an independent predictor of composite end-
point including cardiac death, heart transplantation, unstable VT/VF,
and syncope.
According to available studies on ARVC/D patients, the protocol
of programmed ventricular stimulation should include a minimum of
two drive-cycle lengths and three ventricular extrastimuli while
pacing from two RV sites (apex and RV outflow tract); inducibility
is defined as the induction of either VF or sustained VT, i.e. lasting
.30 s or requiring termination because of haemodynamic
compromise.21,22,25,41
Recent studies showed that demonstration and quantification of
bipolar RV electroanatomic scar area34 as well as identification
of scar-related fractionated electrograms and late potentials35 on
endocardial voltage mapping during EPS may provide significant
added value for arrhythmic risk assessment in ARVC/D. Because
endocardial voltage mapping is an invasive, expensive, and highly
operator-dependent techniquewith a significant riskof inaccurate in-
terpretation of low-voltage recordings in areas of normal myocar-
dium due to suboptimal catheter contact, it is not recommended
as a routine diagnostic tool.
Recommendations
- EPS should be considered in the diagnosis and/or evaluation of
patients with suspected ARVC/D (class IIa).
- Programmed ventricular stimulation may be considered for
arrhythmic risk stratification of asymptomatic ARVC/D patients
(class IIb).
- Endocardial voltage mapping may be considered in the diagnostic
and prognostic evaluation of ARVC/D patients (class IIb).
Follow-up
Patients with ARVC/D should undergo lifelong clinical follow-up to
periodically evaluate new onset or worsening of symptoms,
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progression of morphological and/or functional ventricular abnor-
malities, and ventricular arrhythmias in order to reassess the risk of
SCD and optimize the treatment. Cardiac evaluation of affected
patients including resting 12-lead ECG, echocardiography, 24-h
Holter monitoring, and exercise testing (for detection of
effort-induced ventricular arrhythmias) should be performed on a
regular basis (every 1–2 years) depending on the age, symptoms,
and disease severity.
Due to the age-related penetrance of ARVC/D, healthy gene
carriers and family members should also be offered repeat clinical
assessment (every 2–3 years), mostly during adolescence and
young adulthood.
Therapy
The most important objectives of clinical management of ARVC/D
patients include: (i) reduction of mortality, either by arrhythmic
SCD or death from heart failure; (ii) prevention of disease pro-
gression leading to RV, LV, or biventricular dysfunction and heart
failure; (iii) improvement of symptoms and quality of life by redu-
cing/abolishing palpitations, VT recurrences, or ICD discharges
(either appropriate or inappropriate); and (iv) limiting heart failure
symptoms and increasing functional capacity. Therapeutic options
consist of lifestyle changes, pharmacological treatment, catheter
ablation, ICD, and heart transplantation.
Lifestyle changes
A link has been established between SCD and intense exertion
in young individuals with ARVC/D. Competitive sports activity
has been shown to increase the risk of SCD by five-fold in adolescent
and young adults with ARVC/D.42 Early (i.e. pre-symptomatic)
identification of affected athletes by pre-participation screening
and their disqualification from competitive sports activity may be
‘life-saving’.8,43
In addition, physical exercise has been implicated as a factor pro-
moting development and progression of the ARVC/D phenotype.
Kirchhof et al.44 demonstrated that in heterozygous plakoglobin-
deficient mice, endurance training accelerated the development of
RV dilatation, dysfunction, and ventricular ectopy, suggesting that
chronically increased ventricular load might contribute to worsening
of the ARVC/D phenotype. It has been postulated that impairment of
myocytecell-to-cell adhesionmay lead to tissueandorganvulnerabil-
ity, which may promote myocyte death especially during mechanical
stress, which occurs during competitive sports activity.45,46 Studies in
humans confirmed that endurance sports and frequent exercise in-
crease age-related penetrance, risk of VT/VF, and occurrence of
heart failure in ARVC/D desmosomal-gene carriers.47,48
Recommendations
- It is recommended that patients with a definite diagnosis of
ARVD/C not participate in competitive and/or endurance
sports (Class I).
- Patients with a definite diagnosis of ARVD/C should be restricted
from participation in athletic activities, with the possible excep-
tion of recreational low-intensity sports (Class IIa).
- Restriction from competitive sports activity may be considered
in ARVC/D family members with a negative phenotype, either
healthy gene carriers (class IIa) or with unknown genotype
(class IIb).
Pharmacological therapy
Pharmacological options in ARVC/D treatment consist of anti-
arrhythmic agents, beta-blockers, and heart failure drug therapy.
Antiarrhythmic drugs
The aim of antiarrhythmic drug (AAD) therapy in patients with
ARVC/D is to improve the quality of life by preventing symptomatic
ventricular arrhythmias. There are no prospective and randomized
trials on AAD therapy in ARVC/D and systematic comparison of
treatment strategies.
Moreover, the assessment of efficacy of specific AAD therapy is
difficult because ARVC/D patients tend to have multiple arrhythmic
events over time and drugs are often changed.41,49 Available data are
limited to case–control studies, retrospective analyses, and clinical
registries. Hence, indication for AAD therapy and choice of drug
are based on an empirical approach resulting from extrapolation
from other diseases, personal experience, consensus, and individual
decisions.
The available evidence suggests that amiodarone (loading dose of
400–600 mg daily for 3 weeks and then maintenance dose of 200–
400 mg daily), alone or in combination with beta-blockers, is the
most effective drug for preventing symptomatic ventricular arrhyth-
mias with a relatively low proarrhythmic risk even in patients with
ventricular dysfunction, although its ability to prevent SCD is un-
proved.49 Corrado et al.22 reported that the majority of life-saving
ICD interventions in high-risk patientsoccurred despite concomitant
AADs, a finding supporting the concept that AAD therapy may not
confer adequate protection against SCD.
Recommendations
- AADs are recommended as an adjunct therapy to ICD in ARVC/
D patients with frequent appropriate device discharges (class I).
- The use of AADs should be considered to improve symptoms in
patients with frequent premature ventricular beats and/or non-
sustained VT (class IIa).
- AADs may be considered as an adjunct therapy to catheter
ablation without a back-up ICD in selected ARVC/D patients
with recurrent, haemodynamically stable VT (class IIb).
- AAD treatment of asymptomatic ARVC/D patients without
documented ventricular arrhythmias and healthy gene carriers
is not recommended (class III).
Beta-blockers
Ventricular arrhythmias and cardiac arrest in ARVC/D are frequently
triggered by adrenergic stimulation and occur during or immediately
after physical exercise.8,40,42,47,48 Autonomic dysfunction with
increased sympathetic stimulation of ventricular myocardium and
subsequent reduction of beta-adrenoceptor density was demon-
strated by Wichter et al.50,51 with the use of radionuclide imaging
and quantitative positron emission tomography.
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The indication for the use of beta-blocker drugs in ARVC/D relies
on their proven efficacy to prevent effort-induced ventricular
arrhythmias, their proven efficacy in heart failure management, and
their potential but unproven ability to hinder myocardial disease pro-
gression by lowering RV wall stress.
Because studies are not available to compare the efficacy of indi-
vidual beta-blockers and to define the most effective dosage, we
recommend using non-vasodilating beta-blockers titrated to
maximum tolerated dose for age and weight.
Recommendations
- Beta-blocker therapy is recommended in ARVC/D patients with
recurrent VT, appropriate ICD therapies, or inappropriate ICD
interventions resulting from sinus tachycardia, supraventricular
tachycardia, or atrial fibrillation/flutter with high-ventricular rate
(class I).
- Beta-blocker therapy should be considered in all patients with
ARVD/C irrespective of arrhythmias (class IIa).
- The prophylactic use of beta-blockers in healthy gene carriers is
not recommended (class III).
Preload-reducing drug therapy
Fabritz et al.52,53 provided experimental evidence that ventricular
preload-reducing therapy prevents or tempers the development of
ARVC/D in genetically susceptible murine hearts. Therapy with fur-
osemide and nitrates completely prevented training-induced devel-
opment of RV enlargement and normalized VT inducibility, thereby
rendering treated plakoglobin-deficient mice phenotypically indistin-
guishable from their trained wild-type littermates.
Preload-reducing drug therapy is not yet part of clinical practice
because the results of the animal studies demonstrating its beneficial
effects require validation in other ARVC/D models and patients.
Heart failure and antithrombotic drug
therapy
TheprevalenceofRVorbiventriculardysfunction leading toprogressive
heart failure and death in ARVC/D is variable in the published series,
mostly depending on the selection criteria of patients, whether
referred for arrhythmias or heart failure.20 –27,30– 33,36,39,44,48,54,55
Left-ventricular involvement was originally considered an end-stage
complication of ARVC/D, occurring late during the disease course
and leading ultimately to biventricular pump failure.3,4 More recently,
genotype–phenotype correlations have shown early and greater LV
involvement in genetically predisposed ARVC/D patients.54– 58
In ARVC/D, thromboembolic complications may result from intra-
cardiac thrombus formation intoventricular aneurysms, sacculations,
or ventricular dilatation due to either global or regional ventricular
dysfunction. A retrospective study by Wlodarska et al.59 on 126
ARVC/D patients with severe RV dilatation reported a 0.5% annual
incidence rate of thromboembolic complications during a mean
follow-up period of 99+64 months.
Recommendations
- For ARVC/D patients who developed right- and/or left-sided heart
failure standard pharmacological treatment with angiotensin-
converting-enzyme inhibitors, angiotensin II receptor blockers,
beta-blockers, and diuretics is recommended (class I).
- Long-term oral anticoagulation is generally indicated for second-
ary prevention in patients with documented intracavitary throm-
bosis or venous/systemic thromboembolism (class I).
- For ARVC/D patients with asymptomatic RV and/or LV dysfunc-
tion treatment with angiotensin-converting-enzyme inhibitors or
angiotensin II receptor blockers may be considered (class IIb).
- Prophylactic anticoagulation for primary prevention of thrombo-
embolism on the basis of ventricular dilatation/dysfunction, either
global or regional, is not recommended (class III).
Catheter ablation
Catheter ablation is a therapeutic option for ARVC/D patients who
have VT. Fibrofatty replacement of RV myocardium creates scar
regions that are regarded as arrhythmogenic substrate for VT. Ven-
tricular tachycardia is the result of a scar-related macro-reentry
circuit, similar to that observed in the post-myocardial infarction
setting, which is suitable for mapping and interruption by catheter ab-
lation.Catheter ablationmay be guided by either conventional electro-
physiological or substrate-based mapping during sinus rhythm.60–72
Fontaine et al.60,62 first studied the effects of direct current fulgur-
ation and demonstrated the feasibility of VT ablation in ARVC/D.
Subsequently, several studies have reported on acute and long-term
results of endocardial catheter ablation of VT using radiofrequency
current.63– 73 Overall, acute success was achieved in 60–80% of
patients, whereas the recurrence rates during long-term follow-up
of 3–5 years were as high as 50–70% (see Supplementary material
online,Table S1). The high frequencyof VTrecurrences and the discrep-
ancy between the successful acute results and the unfavourable long-
term outcome have been explained by the progressive nature of the
ARVC/D substrate (i.e. fibrofatty scar), which predisposes to the occur-
rence of multiple reentry circuits and new arrhythmogenic foci over
time.10,68 Recently, studies have suggested that epicardial location of
some VT reentry circuits, which reflects the propensity of ARVC/D
lesion to originate and progress from the epicardium, may partly
explain the failure of conventional endocardial mapping/catheter abla-
tion. Garcia et al.70 first reported the feasibility and efficacy of epicardial
catheter ablation in ARVC/D patients who underwent an epicardial
approach after previously failed endocardial VT mapping/ablation pro-
cedures. In these patients, the extent of electroanatomical scar area at
voltage mapping was larger on the epicardial side of the RV wall than
on the endocardium. Complete success was achieved in 85% of cases
(partial success in 92%) and 77% of patients were free of VT during
18 months of follow-up. Phillips et al.72 compared the efficacy of trad-
itional electrophysiological VT mapping/catheter ablation with other
strategies including substrate-based and epicardial catheter approaches.
The recurrences of VT were significantly reduced irrespective of the
mapping/ablation strategy. The cumulative freedom from VT following
procedures using 3D-electroanatomical mapping and/or epicardial
approachwas significantly greater thanconventional ablation, although
the recurrence rates remain considerable. Freedom from VT after
epicardial ablation of 64 and 45% at 1 and 5 years was found,
which was significantly improved compared with studies using the
endocardial approach. According to Berruezo et al.,71 complete scar
de-channelling with elimination of either endo or epicardial scar
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conducting channels (i.e. intra-scar, inter-scar, or between scar and
valvular annuli) in addition to ablation of clinical VT is a promising
approach to improve long-term success rate of catheter ablation.
According to available data, catheter ablation of VT in ARVC/D
patients should be considered a potentially effective strategy forelim-
inating frequent VT episodes and ICD shocks rather than a curative
therapeutic approach, until long-term efficacy has been consistently
documented. Catheter ablation has not been proved to prevent SCD
and should not be looked upon as an alternative to ICD therapy in
ARVC/D patients with VT, with the exception of selected cases
with a drug refractory, haemodynamically stable, single morphology
VT.22 Additional AAD therapy and repeated ablation procedures as
well as back-up ICD implantation are required to provide clinical
control of VT and SCD prevention.
Recommendations
- Catheter ablation of VT is recommended in ARVC/D patients
with incessant VT or frequent appropriate ICD interventions
on VT despite maximal pharmacological therapy, including amio-
darone (class I).
- Anepicardial approach toVTablation is recommended inpatients
who fail one or more attempts of endocardial VT ablation (class I).
- Catheter ablation of VT should be considered in ARVC/D
patients with incessant VT or frequent appropriate ICD interven-
tions on VT who have failed pharmacological therapy other than
amiodarone (class IIa).
- A combined endocardial/epicardial VT ablation approach as an
initial ablation strategy should be considered, provided that the
operator and electrophysiologic laboratory are experienced per-
forming epicardial VT ablation in patients with ARVC/D (class IIa).
- Catheter ablation of VT may be considered in ARVC/D patients
with incessant VT or frequent appropriate ICD interventions
on VT who have not failed pharmacological therapy and who
do not wish to be treated with pharmacological therapy (class IIb).
- Catheterablation maybe indicated as first choice therapy without
a back-up ICD for selected patients with drug-refractory, haemo-
dynamically stable, single-morphology VT (class IIb).
- Catheter ablation is not recommended as an alternative to ICD
for prevention of SCD in ARVC/D (class III).
Implantable defibrillator therapy
Implantable defibrillator therapy is the most logical therapeutic strat-
egy for patients with ARVC/D, because the natural history is primarily
characterized by the risk of SCD and, only secondarily, by contractile
dysfunction leading to progressive heart failure. Prospective rando-
mized trials are currently not available for ethical reasons and
because of practical limitations predominantly linked to relatively
low disease prevalence and low event rate. The available data,
coming from observational studies/registries of large populations of
ARVC/D patients, have established efficacy and safety of ICD
therapy.22,25,26,28,74 –81 The main results of available studies on ICD
therapy in ARVC/D are summarized in Supplementary material
online, Table S2. These studies consistently document that ICD suc-
cessfully interrupts lethal ventricular tachyarrhythmias and improves
long-term outcome of selected high-risk ARVC/D patients. Overall,
between 48 and 78% of patients received appropriate ICD
interventions during a mean follow-up period of 2–7 years after im-
plantation. Many of these patients experienced multiple ICD dis-
charges during this period and VT storm was not infrequently
reported. In most studies, the survival benefit of the ICD was evalu-
ated by comparing the actual patient survival rate with the projected
freedom of ICD interventions for fast VT (.240 b.p.m.) or VF (i.e.
‘life- saving’ ICD interventions), which were used as a surrogate for
aborted SCD, based on the assumption that these tachyarrhythmias
would have been fatal without termination by the device.22,25,28,77
The endpoint was reached by device interrogation and review of
stored electrocardiograms regarding ICD interventions in response
to fast VT/VF during follow-up. In the largest multicentre study, the
fast VT/VF-free survival rate was 72% at 36 months compared with
the actual patient survival of 98%, with an estimated survival benefit
of 26%.22 The largest single-centre experience found an estimated
improvement of overall survival of 23, 32 and 35% after 1, 3 and 7
years of follow-up, respectively.28 These results were confirmed by
other series reporting rates of life-saving ICD interventions in 30–
50% of patients during follow-up. Despite the relatively short follow-
upof the available studies, the timebetween implantationand the first
appropriate discharge was ≥1 year in a large proportion of patients
with a maximal interval of 5.5 years.25,26,74–81 This finding suggests
that ICD implantation is a lifelong preventive measure with life-saving
interventions occurring even after particularly long phases of
dormant ventricular electrical instability.
It is important to recognize that survival benefitof ICDtreatment is
obtainedat theexpenseof significant complicationsduring follow-up,
with estimated rates of lead/device related complications and in-
appropriate ICD therapies of 3.7%/year and 4.4%/year, respectively
(see Supplementary material online, Table S2). Detailed information
on ICD-related complications in the published ICD studies is pro-
vided by the recent meta-analysis by Schinkel.82 In the long-term
study (80+ 43 months) by Wichter et al.,28 37 of 60 (62%) ARVC/
D patients had a total of 53 serious adverse events (31 lead-related),
10 occurring during the perioperative phase and 43 during follow-up.
This high rate of lead-related adverse events may be explained by the
peculiar ARVC/D pathobiology which leads to progressive loss of
myocardium with fibrofatty replacement, also affecting the site of
RV lead implantation. In this regard, Corrado et al. reported that
4% of ARVC/D patients required an additional septal lead owing
to loss of ventricular sensing/pacing functions at the apical RV free
wall during a follow-up of 3.3 years.22 Therefore, particular attention
should bepaid toprogressive loss ofR-wavesensing amplitude during
follow-up, which may compromise adequate device function and may
indicate disease progression.
Inappropriate ICD interventions occur in 10–25% of patients with
ARVC/D, mostly at young age,77 and are usually caused by sinus
tachycardia or atrial tachyarrhythmia (see Supplementary material
online, Table S2). Inappropriate interventions are painful and may
have a profound clinical and psychological impact on patients.83
The incidence of inappropriate ICD discharges can be lowered by ap-
propriate ICD programming84 and administration of beta-blockers
or sotalol. Although the use of dual-chamber detection algorithms
offers the potential to reduce the number of inappropriate interven-
tions by improving discrimination of ventricular from supraventricu-
lar arrhythmias, an additional lead in atrium predisposes to a higher
incidence of early and late post-operative complications.
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Indications for ICD implantation
The published studies on ARVC/D patients that provided informa-
tion about the independent predictors for major arrhythmic events
(i.e. SCD, cardiac arrest due to VF, sustained VT, and appropriate
ICD interventions) during follow-up (Table 3), have been used to
construct three categories of risk for SCD (high, intermediate, and
low) that were determined by consensus (Figure 1). The recommen-
dations for ICD implantation for each risk category were based not
only on the statistical risk, but also on the general health, socio-
economic factors, the psychological impact and the adverse effects
of the device.
The high-risk category includes patients who experienced cardiac
arrest due to VF or sustained VT. This group of patients has an esti-
mated rate of life-threatening arrhythmic events .10%/year and
most benefits for ICD therapy.22 –24 A prophylactic ICD implantation
is also recommended in patientswith severeRV dysfunction (RV frac-
tional area change ≤17% or RV EF ≤35%) or LV dysfunction (LV EF
≤35%) who are considered at high risk by consensus, even in the
absence of life-threatening ventricular arrhythmias.21,22,27,28,30,39
Because the specific arrhythmic risk of ventricular dysfunction is
still undermined for patients with ARVC/D, the inclusion of this
clinical variable into the high-risk category was based on extrapola-
tion from other cardiomyopathies and personal experience.
The low-risk category comprises probands and relatives without
risk factors as well as healthy gene carriers who show a low rate
of malignant arrhythmic events (estimated annual event rate
,1%/year25,31) over a long-term follow-up and do not require any
treatment, including ICD therapy.
Between the two categories there are ARVC/D patients with ≥1
risk factors who are deemed to have an intermediate risk (estimated
annual event rate between 1 and 10%25,26). Among the consensus
experts there was general agreement that syncope, non sustained
ventricular tachycardia (NSVT), or moderate ventricular dysfunc-
tion, either RV (RV fractional area change between 24 and 17% or
RV EF between 40 and 36%), or left-ventricular (LV EF between 45
and 36%), are ‘major’ risk factor that justify (weight of opinion in
favour of ICD) a prophylactic ICD. On the other hand, there was
general consensus that the other factors reported in Table 3
(‘minor’ risk factors) are associated with a risk of major arrhythmic
events not sufficiently high (or controversial) to warrant systematic
ICD implantation for primary prevention (weight of opinion against
ICD). The decision to implant an ICD in patients of this category
Figure 1 Flow chart of risk stratification and indications to ICD implantation in ARVC/D. Based on the available data on annual mortality rates
associated to specific risk factors, the estimated risk of major arrhythmic events in the high-risk category is .10%/year, in the intermediate
ranges from 1 to 10%/year, and in the low-risk category is ,1%/year. Indications to ICD implantation were determined by consensus taking into
account not only the statistical risk, but also the general health, socioeconomic factors, the psychological impact and the adverse effects of the
device. SCD, sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia; RV, right ventricle; LV, left ventricle. *See the text for
distinction between major and minor risk factors.
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should be made on individual basis, by assessing the overall clinical
profile, the age, the strength of the risk factor identified, the level
of SCD risk that is acceptable to the patient, and the potential risk
of inappropriate interventions and complications.
It is noteworthy that indications for ICD implantation may vary in
different countries as a consequence of several non-clinical factors
such as cultural background, socio-economic conditions, health
system, availability of advanced technology, cost–benefit considera-
tions, and liability. Compared with the conservative approach of
many European countries, the current threshold for decision to
implant an ICD in the USA is lower.13 It is particularly important to
outline the potential risk of inappropriate ICD implants due to a
false diagnosis of ARVC/D based on misinterpretation of imaging
studies including cardiac magnetic resonance.85
Recommendations
- Implantation of an ICD is recommended in ARVC/D patients who
have experienced ≥1 episodes of haemodynamically unstable,
sustained VT or VF (class I).
- Implantation of an ICD is recommended in ARVC/D patients with
severe systolic dysfunction of the RV, LV, or both, irrespective of
arrhythmias (class I).
- Implantation of an ICD should be considered in ARVC/D patients
who have experienced ≥1 episodes of haemodynamically stable,
sustained VT (class IIa).
- Implantation of an ICD should be considered in patients who have
‘major’ risk factors such as unexplained syncope, moderate ven-
tricular dysfunction, or NSVT (class IIa).
- Implantation of an ICD may be considered in patients with ‘minor’
risk factors after a careful discussion of the long-term risks and
benefits of ICD implantation (class IIb).
- Prophylactic ICD implantation is not recommended in asymp-
tomatic ARVC/D patients with no risk factors or healthy gene
carriers (class III).
Device selection
A single-chamber ICD system is recommended in order to minimize
the incidence of long-term lead-related complications, mostly in
young patients.
Experience with ICD therapy consistently highlights the beneficial
effect of antitachycardia pacing which is highly effective in terminating
VT episodes in ARVC/D patients. The precise clinical role of leadless
subcutaneous ICD in patients with ARVC/D remains to be defined.
A decision whether to implant a leadless device needs to be patient
specific, balancing lead-related complications with the likelihood of
recurrent VT that may be effectively pace-terminated.
Additional cardiac resynchronization therapy appears reasonable
for those ARVC/D patients with a LV EF ≤35% and a wide QRS
with a left bundle branch block pattern, even though clinical benefit
is extrapolated from resynchronization therapy in other disease
states.86 Right-ventricular resynchronization therapy has been pro-
posed as a therapy for patients with congenital heart disease and
chronic RV heart failure;87 however, no data are available concerning
the clinical and haemodynamic effects of RV pacing in ARVC/D
patients with RV dysfunction and a wide QRS with right bundle
branch block pattern.
Heart transplantation
Arrhythmogenic right-ventricular cardiomyopathy/dysplasia patients
with untreatable heart failure or uncontrollable ventricular tach-
yarrhythmias may require heart transplantation. Tedford et al.88
reported the Johns Hopkins Registry experience with 18 ARVC/D
patients (61% males; mean age 40+ 14 year) undergoing heart trans-
plantation. The most common indication for cardiac transplantation
was heart failure, with less than one-third of patients receiving trans-
plants for intractable ventricular arrhythmias. Patients who received
heart transplants were significantly younger (mean age at the time of
first symptoms 24+ 13 years) and had a more prolonged clinical
course (time from first symptoms to transplant 15 years) com-
paredwith otherARVC/Dregistryparticipants.One-yearafter trans-
plant, the survival was 94 and 88% of patients were alive at an average
post-transplant follow-up of 6.2+4.8 years.
Heart transplantation is recommended as a final therapeutic
option in ARVC/D patients with either severe, unresponsive con-
gestive heart failure or recurrent episodes of VT/VF which are refrac-
tory to catheter (and surgical) ablation in experienced centres and/or
ICD therapy.
Other surgical therapies
There is currently no clinical role of surgical therapies such as RV
cardiomyoplasty,89 RV disarticulation,90 beating heart cryoablation,91
and left cardiac sympathetic denervation92 in the treatment of patients
with ARVC/D.
Conclusions
The therapeutic management of patients with ARVC/D has evolved
over the years and continues to be an important challenge. To further
improve risk stratification and treatment of patients, more informa-
tion is needed on the natural history, long-term prognosis, and risk
assessment. Special attention should be focused on the identification
of patients who would benefit from ICD implantation in comparison
to pharmacological and other non-pharmacological approaches.
Data from prospective studies/registries with larger number of pa-
tients and longer follow-up as well as data obtained from multicentre
randomized controlled trials are required to provide evidence-based
recommendations for the best care of ARVC/D patients.
Current therapeutic and preventive measures are palliative, not
curative. The definitive cure of ARVC/D will be based on the discov-
ery of the molecular mechanisms that are involved in the aetiology
and pathogenesis of the disease.
Supplementary material
Supplementary material is available at European Heart Journal online.
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